CLL1 CAR-T / Hedy Group, Zhejiang University - LARVOL DELTA

Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies (ASH 2025) - P1/2 | "Background : CD7 chimeric antigen receptor (CAR) T-cell therapy has recently emerged as a promisingstrategy to induce remission of relapsed or refractory (R/R) CD7-positive hematologic malignancies...Lymphodepleting chemotherapy based with fludarabine,cyclophosphamide, and etoposide was administered, followed by infusion of CD7 CAR T cells at a dose of2×10⁶ cells/kg derived either from previous transplant or newly HLA-haploidentical donors...One patient had previously received CLL-1 CAR-T therapy.CD7 CAR T-cell products were successfully manufactured for all patients, which were sourced from newlyselected haploidentical donors in 15 cases (78.9%) and from prior transplant donors in 4 (21.1%)... This interim analyses further supported that this integrative strategy is safe and feasible inR/R CD7-positive malignancies, offering a promising therapeutic option—particularly for patientsineligible for conventional allo-HSCT."

CAR T-Cell Therapy • Clinical • P1 data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Lymphocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • CD7

Dual-armoring of CLL-1 CAR-T cells with IL-18 and an RQR8 suicide switch enhances efficacy and safety in Acute Myeloid Leukemia (ASH 2025) - "The integrated RQR8safety switch enabled significant elimination of CAR-T cells by rituximab within 48h in vitro, completelyabrogating cytotoxicity and cytokine secretion, thereby providing a critical safeguard against potential IL-18-driven cytokine release syndrome or neurotoxicity. IL-18 co-expression significantly enhances the anti-leukemic efficacy of CLL-1 CAR-T cellsagainst AML in vitro and in vivo, without exacerbating on-target/off-tumor toxicity to HSPCs. Theincorporation of the RQR8 safety switch provides a critical safeguard against potential toxicity. This dual-armoring strategy represents a promising novel therapeutic approach for R/R AML."

CAR T-Cell Therapy • Clinical • IO biomarker • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • CXCL10 • IFNG • IL18 • IL21 • IL6